(19)
(11)EP 2 887 964 A1

(12)

(43)Date of publication:
01.07.2015 Bulletin 2015/27

(21)Application number: 13753904.5

(22)Date of filing:  20.08.2013
(51)International Patent Classification (IPC): 
A61K 47/48(2006.01)
A61P 9/04(2006.01)
A61P 13/12(2006.01)
A61P 1/00(2006.01)
A61P 9/12(2006.01)
(86)International application number:
PCT/GB2013/052192
(87)International publication number:
WO 2014/029983 (27.02.2014 Gazette  2014/09)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 21.08.2012 US 201261691635 P

(71)Applicant: Ardelyx, Inc.
Fremont, California 94555 (US)

(72)Inventors:
  • LEADBETTER, Michael
    Fremont, California 94555 (US)
  • BELL, Noah
    Fremont, California 94555 (US)
  • LEWIS, Jason
    Fremont, California 94555 (US)
  • JACOBS, Jeffrey
    Fremont, California 94555 (US)
  • CARRERAS, Christopher
    Fremont, California 94555 (US)

(74)Representative: Storm, Jan Peter et al
AstraZeneca Intellectual Property Pepparedsleden 1
431 83 Mölndal
431 83 Mölndal (SE)

  


(54)COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS